- Home
- LXRX vs LENZ Comparison
LXRX vs LENZ Comparison
Compare LXRX & LENZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LXRX | LENZ |
|---|---|---|
| Founded | 1995 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 547.4M | 609.5M |
| IPO Year | 2000 | 2021 |
Fundamental Metrics
Financial Performance| Metric | LXRX | LENZ |
|---|---|---|
| Price | $1.64 | $13.07 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 4 |
| Target Price | $3.23 | ★ $56.25 |
| AVG Volume (30 Days) | ★ 2.3M | 729.8K |
| Earning Date | 05-04-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 21.25 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $31,081,000.00 | N/A |
| Revenue This Year | $56.61 | N/A |
| Revenue Next Year | N/A | $157.21 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 2481.48 | N/A |
| 52 Week Low | $0.32 | $11.48 |
| 52 Week High | $1.83 | $50.19 |
Technical Indicators
Market Signals| Indicator | LXRX | LENZ |
|---|---|---|
| Relative Strength Index (RSI) | 64.63 | 39.57 |
| Support Level | $1.07 | $11.48 |
| Resistance Level | $1.65 | $30.24 |
| Average True Range (ATR) | 0.10 | 0.91 |
| MACD | 0.02 | 0.27 |
| Stochastic Oscillator | 93.42 | 43.70 |
Price Performance
Historical ComparisonAbout LXRX Lexicon Pharmaceuticals Inc.
Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drug candidates are LX9211, an orally-delivered small molecule drug candidate, also developing LX9851, an orally-delivered small molecule drug candidate, as a treatment for obesity and associated cardiometabolic.
About LENZ LENZ Therapeutics Inc.
LENZ Therapeutics Inc is a late-stage biopharmaceutical company focused on developing and commercializing therapies to improve vision and developing ophthalmic pharmaceutical products.. Its initial focus is the treatment of presbyopia, the inevitable loss of near vision that impacts the daily lives of nearly all people over 45.